Scientists are racing to work out if existing vaccines will work against the new variants. Photo / AP
ANALYSIS:
Viruses, it turns out, have something in common with buses. You wait the best part of a year for a new variant to come along and then three or four turn up at once - each a little faster, fitter and stronger than those that went before.
Such is the evolutionary advantage acquired by the "UK variant" that it has been described as causing a "pandemic within a pandemic". The chaos it has wreaked since first getting a grip in November was this weekend predicted to come to a crescendo in the capital.
"For London, for critical care, it'll be the next 100 hours that'll count. That's when the crescendo will play out - and this is when we need all our heroes", Geoff Bellingan, professor of critical care medicine at University College London, tweeted on Friday.
A third national lockdown in England and the extraordinary work of doctors such as Bellingan should see the country through the surge but the attack of the mutants is far from over.
Even as new cases start to fall in Britain, other variants of SARS-CoV-2 with perhaps greater potency are springing up across the world.
In South Africa, variant 501.V2 is already dominant in the Eastern and Western Cape provinces and is thought to be responsible for the country's ferocious second wave.
And in Brazil, a variant called P1 is causing terrible carnage. Hospitals in Manaus in the north of the country have again reached breaking point. This is despite up to three quarters of the city's population contracting Covid-19 last year. "There is no oxygen and lots of people are dying. If anyone has any oxygen, please bring it to the clinic. There are so many dying," a medical worker was filmed pleading in a widely shared video from the region.
Virologists are not sure why so many variants of the virus are now - a year into the pandemic - on the march but nor do they think it is a coincidence. Mutations of the virus, it is suggested, are somehow converging. Each has sprung up independently in a different part of the world, but all share a remarkably similar constellation of genetic changes which confer a common advantage.
"After 10 months of relative quiescence we've started to see some striking evolution of SARS-CoV-2 with a repeated evolutionary pattern in the variants of concern emerging from the UK, South Africa and Brazil," Trevor Bedford, professor of epidemiology and genome sciences at the University of Washington, wrote on Twitter.
Bedford speculates the pattern is explained by the virus coming under a common pressure to mutate. Specifically, he thinks that they may have emerged from hospitalised patients who have struggled a long time against the disease.
"My (highly speculative!) hypothesis is that the emergence of these variant viruses arises in cases of chronic infection during which the immune system places great pressure on the virus to escape immunity and the virus does so by getting really good at getting into cells," he added.
"The fact we've observed three variants emerge since September suggests that there are likely more to come."
Britain's long-term strategic defence against Covid mutations and indeed future pandemic pathogens is being built in a field in rural Oxfordshire. From the outside, it looks like just another large industrial shed but when completed at the end of this year, the Vaccines Manufacturing and Innovation Centre (VMIC) being built at breakneck speed at Harwell Science & Innovation Campus will have the capacity to make sufficient doses of nearly any vaccine within months.
Oxfordshire based Vaccines Manufacturing and Innovation Centre (VMIC) in Oxfordshire expands with 50 new jobs. @BizInnovateMag #BusinessExpansion #Lifesciences #Innovationhttps://t.co/beIObdCT3z pic.twitter.com/uPRYkBh1cu
— Greybridge (@GreybridgeRoles) November 18, 2020
Matthew Duchars, chief executive of the VMIC, concedes that the project came too late to help with the first waves of Covid-19, but says it will be fully operational by December.
It will be capable of producing conventional vaccines as well as the new RNA jabs pioneered by Pfizer and Moderna. As such it will be well placed to see off any new variants of the virus that emerge to evade the protection provided by existing products, he says.
"We will be able to make 70 million doses [of vaccine] in a four-to-five-month period", he told The Telegraph on Friday. "The new Covid variants are absolutely part of the thinking."
Scientists around the world are already racing to work out if existing Covid vaccines will work against the known new variants. And the good news is most think that they will. The variants are all characterised by a series of small changes to the spike protein, the part of the virus that attaches to cells. They seem to have made the virus more transmissible but do not appear significant enough to evade the antibodies produced by existing vaccines.
"If over 90 per cent of the protein remains unchanged, 90 per cent of the antibodies being produced would still be completely effective," says Prof Beate Kampmann, director of the Vaccine Centre at the London School of Hygiene and Tropical Medicine.
Data from Pfizer/BioNTech show promising signs that its jab will hold off the variants, and Prof Danny Altmann, at Imperial College London, has similar data of his own. But he warns: "There are new mutations all the time, but occasionally one will throw up a nasty variant. This will come back to bite us if we don't address it."
The Oxford AstraZeneca team is working on new vaccines should they be needed and "starting the processes needed for rapid development of adjusted Covid-19 vaccines".
Ugur Sahin, Pfizer's chief executive, has previously said a tweaked vaccine could be developed in six weeks if needed due to the revolutionary new technology they use. It is hoped regulators will be able to give the nod to tweaked vaccines more quickly, in the style of the annual flu jab adapted each year to tackle the most prevalent strain.
However, for flu there are "sentinel" labs across the globe dedicated to constantly tracking new strains. For SARS-CoV-2, global surveillance is in its infancy and much more limited as a result.
Scientists say a "cat and mouse" game lies ahead, as vaccine producers scramble to keep up with the mutating virus. Unless we up our surveillance game quickly and see the virus changing before it hits, it's a game we are at risk of playing blind, say experts.
The new VMIC facility in Oxfordshire will provide Britain with better long-term defences when it comes on stream in 12 months' time. But until then the battle against the mutants will be fought largely with imported vaccines and crude non-pharmaceutical interventions, most notably social distancing.
In a best-case scenario, data will start to arrive in a few weeks which show the current vaccines are effective at protecting the most vulnerable against severe Covid-19, including that caused by the new variants.
The absolute nightmare, say scientists, is if a new vaccine-resistant variant emerges ahead of next winter and before the VMIC is built.
If that happens the whole process may need to be started all over again.
New York Times: Ballot boxes burn as America faces unprecedented election violence.